Genmab — November 2015
-
Janssen‘s first DuoBody under the Genmab collaboration, EM1, will enter the clinic in December 2015 in non-small-cel lung cancer, and carries a significant milestone. Blogbuster member S.O. was keen enough to point this out this morning since nothing has been officially announced yet
-
-
-
Characterizing the whac-a-mole concept of a bispecific antibody targeting cancer cells – Atlas of Science
One of the great promises of antibodies is to be magic bullets that specifically target diseased cells without affecting normal cells. Oncology researchers identify targets on tumor cells that are unique, overexpressed, or oncogenic drivers that can be specifically targeted with antibodies in order...
(atlasofscience.org)
-
Genmab owns all improvements made to the technology based on the feedback provided by Janssen and its experience with the DuoBody platform. Det er jo lige netop dette Jan flere gang har nævnt, at man skulle bruge BP til i disse første kommercielle aftaler
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind